1 Surprising Stock Drop that Makes Perfect Sense

Editor's Note: This video was filmed May 7th.

Biotechs Aegerion Phamaceuticals (NASDAQ: AEGR  ) and Isis Pharmaceuticals (NASDAQ: ISIS  ) reported earnings last week, and the market reacted pretty negatively to the news --  Isis lost about 4% after reporting, while Aegerion cratered 25%. Looking at the numbers, you might wonder if that was a transcription error.

After all, it was Isis whose revenue dropped to $28 million from $43 million in the year-ago first quarter. Isis also reported a wider loss, with a $0.27 loss per share comparing unfavorably to a $0.02 loss in first quarter of 2013. And Aegerion increased revenue -- in fact, it roughly doubled it to $40 million from $19 million in the year-ago quarter. And the company narrowed its net loss from $0.64 per share to $0.54 per share.

So, what happened?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson lay out why Aegerion lost so much more than Isis -- how analyst expectations and weaker-than-expected sales of the drug Juxtapid combined to sink the stock last week.

This top stock could make perfect sense for your portfolio
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 16, 2014, at 4:32 PM, Rifleman3006 wrote:

    You can't survive on one drug, especially when it's so high priced. The payor industry is trying to reduce the availability of high priced drugs not increase them. There is NOTHING that says the insurance carriers have to provide their members with such highpriced drugs such as juxtapid and I promise you they will not in the end.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2958537, ~/Articles/ArticleHandler.aspx, 11/27/2014 4:59:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement